|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||223.269 g/mol g·mol−1|
|3D model (JSmol)|
|(what is this?)|
Suritozole (MDL 26,479) is an investigational cognition enhancer. It acts as a partial inverse agonist at the benzodiazepine receptor site on the GABAA ion channel complex, but does not have either anxiogenic or convulsant effects, unlike other BZD inverse agonists such as DMCM. It was investigated for the treatment of depression and Alzheimer's disease, but clinical development seems to have been discontinued.
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|